JP6184960B2 - メラトニンの新規用途 - Google Patents
メラトニンの新規用途 Download PDFInfo
- Publication number
- JP6184960B2 JP6184960B2 JP2014530214A JP2014530214A JP6184960B2 JP 6184960 B2 JP6184960 B2 JP 6184960B2 JP 2014530214 A JP2014530214 A JP 2014530214A JP 2014530214 A JP2014530214 A JP 2014530214A JP 6184960 B2 JP6184960 B2 JP 6184960B2
- Authority
- JP
- Japan
- Prior art keywords
- melatonin
- dietary supplement
- symptoms
- sublingual
- hangover
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Addiction (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
Claims (7)
- メラトニン又はその医薬的に許容される塩を含む、急性アルコール中毒、二日酔いの症状又は急性のアルコール摂取後の身体機能低下を治療する医薬であって、前記メラトニンの投与量が就寝前に1回で0.1〜5mgである、医薬。
- 吸入エアゾル、舌下、経皮、経鼻、経口、直腸、静脈内投与からなる群から選択される形態である、請求項1に記載の医薬。
- 遅延形態ではない、請求項1又は2に記載の医薬。
- メラトニン又はその医薬的に許容される塩を含む、二日酔いの症状、又は急性のアルコール摂取後の身体機能低下を回避するための栄養補助食品であって、前記メラトニンの投与量が就寝前に1回で0.1〜5mgである、栄養補助食品。
- 遅延形態ではない、請求項4に記載の栄養補助食品。
- 前記メラトニンの投与量が就寝前に1回で1.5〜3mgである、請求項4又は5に記載の栄養補助食品。
- 前記栄養補助食品が、舌下ストリップ又は舌下液として投与される形態である、請求項4〜6のいずれか1項に記載の栄養補助食品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20110181683 EP2570126B1 (en) | 2011-09-16 | 2011-09-16 | Use of melatonin for treating acute alcohol intoxication |
EP11181683.1 | 2011-09-16 | ||
PCT/EP2012/067933 WO2013037883A1 (en) | 2011-09-16 | 2012-09-13 | New use of melatonine |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014526488A JP2014526488A (ja) | 2014-10-06 |
JP6184960B2 true JP6184960B2 (ja) | 2017-08-23 |
Family
ID=46851981
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014530214A Active JP6184960B2 (ja) | 2011-09-16 | 2012-09-13 | メラトニンの新規用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10179122B2 (ja) |
EP (1) | EP2570126B1 (ja) |
JP (1) | JP6184960B2 (ja) |
CN (1) | CN103813791B (ja) |
AU (1) | AU2012307430B2 (ja) |
CA (1) | CA2848231C (ja) |
RU (1) | RU2633484C2 (ja) |
WO (1) | WO2013037883A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220016093A1 (en) * | 2018-12-07 | 2022-01-20 | Ajay Suman | Compositions for Aiding Liver Function |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2718020B1 (fr) | 1994-04-01 | 1996-05-31 | Biotec Centre Sa | Composition galénique mucoadhésive hétérofonctionnelle. |
EP0867181A1 (en) | 1997-03-26 | 1998-09-30 | Franciscus Wilhelmus Henricus Maria Merkus | Nasal melatonin composition |
KR100257448B1 (ko) | 1997-08-01 | 2000-07-01 | 박홍락 | 항암, 기관분화유도, 암세포전이 혈관형성억제, 항산화 및 숙취해소 작용을 하는 옻나무 추출물, 이의 제조방법 및 이를 포함하는 조성물 |
US20020048551A1 (en) * | 1999-04-06 | 2002-04-25 | Keller Brian C. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
IL149377A (en) * | 2002-04-28 | 2012-10-31 | Neurim Pharma 1991 | Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds |
UA55668A (uk) | 2002-04-12 | 2003-04-15 | Інститут Геронтології Академії Медичних Наук України | Спосіб лікування та попередження порушень діяльності серцево-судинної системи стресового походження у людей літнього віку |
EP1684737A4 (en) | 2003-11-07 | 2009-11-11 | Oaky Natural Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING GAIACOL DERIVATIVES AND SYRINGOL DERIVATIVES EXTRACTED FROM NATURAL VEGETABLE VINEGAR |
AU2004308962A1 (en) | 2003-12-24 | 2005-07-14 | Sepracor Inc. | Melatonin combination therapy for improving sleep quality |
RU2250778C1 (ru) | 2004-02-26 | 2005-04-27 | Мясников Дмитрий Николаевич | Средство, снижающее неблагоприятные последствия острой алкогольной интоксикации |
WO2006118358A1 (en) | 2005-05-02 | 2006-11-09 | Cj Corporation | Composition for preventing and treating hangover |
GB2434099A (en) | 2006-01-12 | 2007-07-18 | Roger Coghill | Very low dosage melatonin compositions and their use in the treatment of the adverse effects of exposure to electromagnetic fields and radiation |
US20070298133A1 (en) | 2006-06-23 | 2007-12-27 | The Procter & Gamble Company | Compositions and kits comprising a melatonin component and a flavanol component |
US20080167363A1 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc | Modulation of Neurogenesis By Melatoninergic Agents |
US20100119601A1 (en) | 2007-04-11 | 2010-05-13 | Pharmaceutical Productions Inc. | Melatonin tablet and methods of preparation and use |
CN101754753A (zh) | 2007-05-24 | 2010-06-23 | 纽约市哥伦比亚大学托管会 | 褪黑素的持久释放配方 |
WO2012029898A1 (ja) * | 2010-09-01 | 2012-03-08 | 日本水産株式会社 | アルコール性障害緩和剤 |
-
2011
- 2011-09-16 EP EP20110181683 patent/EP2570126B1/en active Active
-
2012
- 2012-09-13 RU RU2014115196A patent/RU2633484C2/ru active
- 2012-09-13 CA CA2848231A patent/CA2848231C/en active Active
- 2012-09-13 JP JP2014530214A patent/JP6184960B2/ja active Active
- 2012-09-13 CN CN201280043949.9A patent/CN103813791B/zh active Active
- 2012-09-13 WO PCT/EP2012/067933 patent/WO2013037883A1/en active Application Filing
- 2012-09-13 US US14/344,999 patent/US10179122B2/en active Active
- 2012-09-13 AU AU2012307430A patent/AU2012307430B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
RU2633484C2 (ru) | 2017-10-12 |
AU2012307430B2 (en) | 2017-08-31 |
EP2570126A1 (en) | 2013-03-20 |
CA2848231C (en) | 2019-12-31 |
US20150111941A1 (en) | 2015-04-23 |
JP2014526488A (ja) | 2014-10-06 |
RU2014115196A (ru) | 2015-10-27 |
CN103813791A (zh) | 2014-05-21 |
AU2012307430A1 (en) | 2014-04-17 |
CA2848231A1 (en) | 2013-03-21 |
US10179122B2 (en) | 2019-01-15 |
CN103813791B (zh) | 2016-06-15 |
WO2013037883A1 (en) | 2013-03-21 |
EP2570126B1 (en) | 2014-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5513126B2 (ja) | 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 | |
JP2014528474A5 (ja) | ||
RU2707089C2 (ru) | Комбинированная композиция | |
JP2018507243A5 (ja) | ||
KR102597910B1 (ko) | 숙취상태와 연관된 증상들을 억제하기 위한 방법 및 조성물 | |
Gautam et al. | Evaluation of the efficacy of methylprednisolone, etoricoxib and a combination of the two substances to attenuate postoperative pain and PONV in patients undergoing laparoscopic cholecystectomy: a prospective, randomized, placebo-controlled trial | |
JP2024026871A (ja) | 慢性便秘症を治療するための医薬組成物 | |
JP6184960B2 (ja) | メラトニンの新規用途 | |
WO2004080414A2 (en) | Composition and method for treating inflammations by reducing c-reactive protein | |
TW201249450A (en) | Sweet tea olive extract and manufacturing method and use thereof, as well as the composition comprising the sweet tea olive extract for prevention or treatment of melancholia | |
TW200831072A (en) | Non-steroidal anti-inflammatory drugs for cough | |
CN109646438A (zh) | 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用 | |
JPWO2019237054A5 (ja) | ||
US11464756B1 (en) | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof | |
JP7034314B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
CN106728747A (zh) | 一种治疗灰指甲的中医药物配方 | |
EP4181887A1 (en) | Pde3 inhibitors for treating viral infections | |
RU2131733C1 (ru) | Способ ослабления и профилактики абстинентного синдрома и средство для его осуществления | |
WO2022126255A1 (en) | Antioxidant nutritional supplement for immune system support | |
CN107648226A (zh) | 一种治疗偏头痛的药物组合物及其制备方法 | |
CN106728023A (zh) | 一种治疗胆结石的中医药物配方 | |
JP2006151987A (ja) | ビタミンcとカルシウムによる睡眠剤 | |
RU2018133603A (ru) | Пероральная дозированная форма двух изомеров кломифена и способ ее использования для лечения вторичного гипогонадизма и минимизации побочных эффектов лекарственного препарата у мужчин | |
CN108014178A (zh) | 一种治疗胆结石的中医药物配方 | |
Vital | Flavogard (Pycnogenol) may protect from five major cardiovascular risk factors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150814 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161216 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170316 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170516 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170726 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6184960 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |